AU2016394945A1 - Aminobenzimidazole derivatives - Google Patents

Aminobenzimidazole derivatives Download PDF

Info

Publication number
AU2016394945A1
AU2016394945A1 AU2016394945A AU2016394945A AU2016394945A1 AU 2016394945 A1 AU2016394945 A1 AU 2016394945A1 AU 2016394945 A AU2016394945 A AU 2016394945A AU 2016394945 A AU2016394945 A AU 2016394945A AU 2016394945 A1 AU2016394945 A1 AU 2016394945A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
group
nhr
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016394945A
Other languages
English (en)
Inventor
Stephen Gately
Tong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translational Drug Development LLC
Original Assignee
TRANSLATIONAL DRUG DEV LLC
Translational Drug Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRANSLATIONAL DRUG DEV LLC, Translational Drug Development LLC filed Critical TRANSLATIONAL DRUG DEV LLC
Publication of AU2016394945A1 publication Critical patent/AU2016394945A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016394945A 2016-03-02 2016-05-23 Aminobenzimidazole derivatives Abandoned AU2016394945A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302781P 2016-03-02 2016-03-02
US62/302,781 2016-03-02
PCT/US2016/033841 WO2017151165A1 (en) 2016-03-02 2016-05-23 Aminobenzimidazole derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020267222A Division AU2020267222B2 (en) 2015-05-22 2020-11-11 Benzamide and active compound compositions and methods of use

Publications (1)

Publication Number Publication Date
AU2016394945A1 true AU2016394945A1 (en) 2018-10-11

Family

ID=59744272

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016394945A Abandoned AU2016394945A1 (en) 2016-03-02 2016-05-23 Aminobenzimidazole derivatives

Country Status (8)

Country Link
US (1) US20190040017A1 (enExample)
EP (1) EP3423439A4 (enExample)
JP (1) JP6768078B2 (enExample)
CN (1) CN109071460B (enExample)
AU (1) AU2016394945A1 (enExample)
CA (1) CA3053238A1 (enExample)
IL (1) IL261201B (enExample)
WO (1) WO2017151165A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031655B1 (ru) 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
JP6688735B2 (ja) 2014-02-11 2020-04-28 バイエル・ファルマ・アクティエンゲゼルシャフト ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン
JP7080234B2 (ja) * 2016-11-23 2022-06-03 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー ベンズアミドおよび活性化合物組成物および使用方法
JP2020533316A (ja) * 2017-09-06 2020-11-19 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー アミノベンゾイミダゾール誘導体、治療、およびヒストン脱アセチル化酵素を阻害する方法
TW202310832A (zh) * 2021-07-21 2023-03-16 日商卡爾那生物科學公司 新穎1,2-二胺基苯并咪唑衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009528384A (ja) * 2006-03-02 2009-08-06 スミスクライン・ビーチャム・コーポレイション Ｐｉ３キナーゼ阻害剤として用いるためのチアゾロン
US9125901B2 (en) * 2009-06-23 2015-09-08 The Translational Genomics Research Institute 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof
US9014282B2 (en) * 2011-05-27 2015-04-21 Cisco Technology, Inc. Precision timing in a data over cable service interface specification (DOCSIS) system
CA2889987A1 (en) * 2012-11-05 2014-05-08 Celgene Corporation Treatment of cancer with pomalidomide in a renally impaired subject
CN114907271B (zh) * 2015-05-22 2024-05-07 转化药物开发有限责任公司 苯甲酰胺和活性化合物的组合物及其使用方法
JP6824954B2 (ja) * 2015-07-16 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール

Also Published As

Publication number Publication date
WO2017151165A1 (en) 2017-09-08
JP2019511485A (ja) 2019-04-25
EP3423439A1 (en) 2019-01-09
CN109071460A (zh) 2018-12-21
IL261201B (en) 2022-01-01
JP6768078B2 (ja) 2020-10-14
US20190040017A1 (en) 2019-02-07
IL261201A (en) 2018-10-31
CA3053238A1 (en) 2017-09-08
EP3423439A4 (en) 2019-08-14
CN109071460B (zh) 2022-08-09

Similar Documents

Publication Publication Date Title
US10590088B2 (en) 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof
US8987468B2 (en) Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
US9221773B2 (en) Benzamide derivatives
AU2016394945A1 (en) Aminobenzimidazole derivatives
US11780816B2 (en) Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase
HK1260272B (en) Aminobenzimidazole derivatives
HK1260272A1 (en) Aminobenzimidazole derivatives
HK1204227B (en) Benzamide derivatives

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application